Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00101270
First received: January 7, 2005
Last updated: June 4, 2013
Last verified: June 2013
  Purpose

This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer cells.


Condition Intervention Phase
Childhood Burkitt Lymphoma
Childhood Central Nervous System Germ Cell Tumor
Childhood Diffuse Large Cell Lymphoma
Childhood Grade III Lymphomatoid Granulomatosis
Childhood Immunoblastic Large Cell Lymphoma
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Cerebral Astrocytoma
Recurrent Childhood Ependymoma
Recurrent Childhood Grade III Lymphomatoid Granulomatosis
Recurrent Childhood Large Cell Lymphoma
Recurrent Childhood Liver Cancer
Recurrent Childhood Lymphoblastic Lymphoma
Recurrent Childhood Malignant Germ Cell Tumor
Recurrent Childhood Medulloblastoma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Childhood Small Noncleaved Cell Lymphoma
Recurrent Childhood Soft Tissue Sarcoma
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Recurrent Childhood Visual Pathway Glioma
Recurrent Colon Cancer
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Melanoma
Recurrent Nasopharyngeal Cancer
Recurrent Neuroblastoma
Recurrent Osteosarcoma
Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Recurrent/Refractory Childhood Hodgkin Lymphoma
Unspecified Childhood Solid Tumor, Protocol Specific
Drug: irinotecan hydrochloride
Drug: oxaliplatin
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • MTD of oxaliplatin, defined as the maximum dose at which fewer than one-third of patients experience DLT [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Graded using the NCI CTCAE version 3.0.


Secondary Outcome Measures:
  • Overall response assessed using RECIST criteria [ Time Frame: Up to 12 months ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: March 2005
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (irinotecan hydrochloride, oxaliplatin)
Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
Drug: irinotecan hydrochloride
Given IV
Other Names:
  • Campto
  • Camptosar
  • CPT-11
  • irinotecan
  • U-101440E
Drug: oxaliplatin
Given IV
Other Names:
  • 1-OHP
  • Dacotin
  • Dacplat
  • Eloxatin
  • L-OHP

Detailed Description:

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of oxaliplatin when administered with irinotecan in pediatric patients with refractory solid tumors or lymphomas.

II. Determine the toxic effects of this regimen in these patients. III. Determine the pharmacokinetics of this regimen in these patients.

SECONDARY OBJECTIVES:

I. Determine, preliminarily, the antitumor activity of this regimen in these patients.

II. Correlate UGT and BCRP genotype with the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter, dose-escalation study of oxaliplatin.

Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

  Eligibility

Ages Eligible for Study:   1 Year to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed refractory malignant solid tumor or lymphoma

    • Intrinsic brain stem tumors and optic pathway tumors do not require histologic verification
  • No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists
  • Measurable or evaluable disease

    • Evaluable disease is defined as a tumor that cannot be measured using a ruler or calipers, but can be assessed to determine disease progression or complete response, such as any of the following:

      • Positive lesions on metaiodobenzylguanidine (MIBG) or bone scan
      • Metastatic bone marrow disease
      • Elevated tumor markers
      • Presence of a malignant pleural effusion
  • No leukemia
  • Performance status - Karnofsky 50-100% (for patients > 10 years of age)
  • Performance status - Lansky 50-100% (for patients ≤ 10 years of age)
  • Not specified
  • Absolute neutrophil count ≥ 1,000/mm^3
  • Platelet count ≥ 100,000/mm^3 (transfusion independent)
  • Hemoglobin ≥ 8.0 g/dL (transfusion allowed)
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • ALT ≤ 5 times ULN
  • Albumin ≥ 2 g/dL
  • Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
  • Creatinine based on age as follows:

    • No greater than 0.8 mg/dL (for patients age 5 and under)
    • No greater than 1.0 mg/dL (for patients age 6 to 10)
    • No greater than 1.2 mg/dL (for patients age 11 to 15)
    • No greater than 1.5 mg/dL (for patients age 16 and over)
  • No arrhythmia on EKG
  • No evidence of dyspnea at rest
  • No exercise intolerance
  • Pulse oximetry > 94% on room air and no evidence of pulmonary fibrosis by chest radiograph* or CT scan
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Weight ≥ 10 kg
  • Neurologic deficits relatively stable for ≥ 1 week before study entry (patients with CNS tumors only)
  • No electrolyte (e.g., sodium, potassium, bicarbonate, calcium, magnesium, and phosphate) abnormality ≥ grade 2 (electrolyte supplementation allowed)
  • No uncontrolled infection
  • No history of life-threatening allergy to camptothecin derivatives or platinum agents
  • No sensory or motor peripheral neuropathy ≥ grade 2
  • No elevation of amylase or lipase ≥ grade 2
  • Able to tolerate enteral medications (e.g., cefixime, cefpodoxime, or loperamide)
  • Recovered from all prior immunotherapy
  • At least 7 days since prior hematopoietic growth factors
  • At least 7 days since prior antineoplastic biologic therapy
  • Prior stem cell transplantation or rescue without total-body irradiation (TBI) allowed provided ≥ 3 months have elapsed and there is no evidence of active graft-versus-host disease
  • No concurrent immunotherapy
  • No concurrent biologic therapy
  • More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
  • No prior oxaliplatin
  • No other concurrent chemotherapy
  • Concurrent steroids allowed provided dose has been stable for ≥ 7 days before study entry
  • See Biologic therapy
  • Recovered from all prior radiotherapy
  • At least 2 weeks since prior local palliative small port radiotherapy
  • At least 6 months since prior TBI
  • At least 6 months since prior craniospinal, whole spinal, or whole lung/abdominal radiotherapy
  • At least 6 months since prior radiotherapy to ≥ 50 % of the pelvis
  • At least 6 weeks since other prior substantial radiotherapy to the bone marrow
  • No concurrent radiotherapy
  • No other concurrent investigational drugs
  • No other concurrent anticancer therapy
  • No concurrent cephalosporin antibiotics
  • No concurrent use of any of the following:

    • Phenytoin
    • Carbamazepine
    • Oxcarbazepine
    • Barbiturates
    • Rifampin
    • Phenobarbital
    • Azole antifungal agents
    • Aprepitant
    • Hypericum perforatum (St. John's wort)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00101270

Locations
United States, California
COG Phase I Consortium
Arcadia, California, United States, 91006-3776
Sponsors and Collaborators
Investigators
Principal Investigator: Lisa McGregor COG Phase I Consortium
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00101270     History of Changes
Other Study ID Numbers: NCI-2012-01819, ADVL0415, CDR0000401518, COG-ADVL0415, U01CA097452
Study First Received: January 7, 2005
Last Updated: June 4, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Astrocytoma
Burkitt Lymphoma
Colonic Neoplasms
Ependymoma
Glioma
Hodgkin Disease
Kidney Neoplasms
Liver Neoplasms
Lymphoma
Lymphoma, Non-Hodgkin
Lymphomatoid Granulomatosis
Medulloblastoma
Melanoma
Wilms Tumor
Neuroblastoma
Osteosarcoma
Rhabdomyosarcoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Immunoblastic
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Nasopharyngeal Neoplasms
Neoplasms, Germ Cell and Embryonal
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Rhabdomyosarcoma, Embryonal
Sarcoma
Optic Nerve Glioma
Lymphoma, Extranodal NK-T-Cell
Neoplasms
Sarcoma, Ewing's

ClinicalTrials.gov processed this record on April 17, 2014